EyePoint Pharmaceuticals, Inc.
EYPT
$5.68
$0.1252.25%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Net Income | -130.87M | -103.57M | -86.82M | -78.92M | -70.80M |
| Total Depreciation and Amortization | 1.54M | 1.19M | 892.00K | 662.00K | 464.00K |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 30.88M | 27.85M | 25.87M | 22.64M | 13.32M |
| Change in Net Operating Assets | -27.77M | -38.95M | -29.60M | 43.15M | 58.88M |
| Cash from Operations | -126.23M | -113.49M | -89.66M | -12.46M | 1.88M |
| Capital Expenditure | -4.05M | -4.55M | -4.70M | -4.19M | -3.48M |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -215.30M | -165.99M | -183.76M | -10.40M | 168.00K |
| Cash from Investing | -219.36M | -170.54M | -188.46M | -14.60M | -3.32M |
| Total Debt Issued | -- | 0.00 | 0.00 | 0.00 | 5.30M |
| Total Debt Repaid | -105.00K | -73.00K | 0.00 | -35.31M | -45.81M |
| Issuance of Common Stock | 169.31M | 235.75M | 234.48M | 233.86M | 229.55M |
| Repurchase of Common Stock | -4.51M | -4.51M | -4.43M | -4.36M | -169.00K |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -672.00K | -343.00K | -758.00K | -1.89M | -1.80M |
| Cash from Financing | 164.02M | 230.82M | 229.29M | 192.30M | 187.07M |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -181.56M | -53.21M | -48.83M | 165.25M | 185.63M |